Zelluna Immunotherapy announced raising EUR 7.5 million in equity financing and public grants.

Zelluna Immunotherapy, an Oslo, Norway-based biopharma company, announced securing funding of EUR 7.5 million ($8.4M).

The money was provided in equity financing and public grants and will be used for the development of its proprietary TCR guided Natural Killer (NK) cell therapy platform (TCR-NK) and novel TCR-NK products for the treatment of cancers.

Zelluna Immunotherapy, founded in 2016 and led by CEO Namir Hassan, is a biopharma company developing “off-the-shelf” T-cell receptor (TCR) guided natural killer (NK) cell therapy products for the treatment of multiple solid cancers. The company is developing a unique portfolio of tumor specific TCR’s that target the MHC class II pathway to broadly engage the host immune system to provide a safe, efficient and durable clinical response. The company is developing therapies based on the effector functions of autologous T cells (TCR-T) and allogeneic NK cells (TCR-NK). Both of these platforms have their unique advantages and provides the opportunity to attack cancers from multiple angles and improve access to these advanced therapies to a large patient population.